ArticleJournal of cancer research and clinical oncology2025
Diagnostic performance of node-RADS classification for primary lymph node assessment in rectal cancer: a modality benchmarking study.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of Node-RADS for lymph node metastasis in rectal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- CT-based Node-RADS classification in the assessment of rectal cancer: diagnostic performance and postoperative prognostic stratification.BMC cancer · 2026Article
- MRI Dark-Light-Dark Sign and Node Reporting Score: An Integrated Model for Predicting Lymph Node Metastasis in Rectal Cancer.Journal of clinical medicine · 2026Article
- Diagnostic and prognostic performance of MRI-based Node-RADS for regional lymph node assessment in treatment-naive rectal cancer.European radiology · 2026Article
- A head-to-head comparison of MRI and CT using Node-RADS for rectal cancer lymph nodes: Observer agreement and diagnostic performance.European journal of radiology open · 2026Article
- The predictive value of contrast-enhanced CT characteristics combined with composite inflammatory markers for lymph node metastasis in T1 colorectal cancer.International journal of colorectal disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo evaluate how well the Node Reporting and Data System (Node-RADS) diagnoses lymph node involvement (LNI) in the initial stages of rectal cancer, utilizing contrast-enhanced CT (CE-CT), T2-weighted MRI (T2WI) and contrast-enhanced T1-weighted MRI (T1CE).
methodsThis retrospective study included 113 rectal cancer patients who underwent radical surgery without neoadjuvant therapy. Two radiologists independently assessed regional lymph nodes using the highest NODE-RADS classification and histopathology as reference criteria. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. Statistical analysis was performed using the McNemar test with Bonferroni correction for multiple comparisons.
resultsNode-RADS showed improved diagnostic performance over short-axis diameter (SAD) in all modalities (AUC: 0.838 vs. 0.744 for CE-CT, 0.845 vs. 0.747 for T2WI, 0.853 vs. 0.786 for T1CE; all P < 0.05). The sensitivity and specificity of Node-RADS across three modalities ranged from 76.19 - 78.57% and 91.55 - 92.96%, respectively. Pairwise comparisons of sensitivity and specificity among the three modalities showed no significant differences after Bonferroni correction (all McNemar test P = 1.0). There was no significant difference in Node-RADS performance among the three modalities (all P > 0.05). The weighted kappa values were 0.742-0.798.
conclusionNode-RADS demonstrated superior diagnostic performance over SAD measurements and similar diagnostic effectiveness in assessing LNI for primary rectal cancer stages across CE-CT, T2WI, and T1CE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.